Cyclacel pharmaceuticals achieves key business objectives in first half of 2022 and continues to advance clinical pipeline

- completed enrollment in phase 1 dose escalation with oral fadraciclib in solid tumors -
CYCC Ratings Summary
CYCC Quant Ranking